CELLBANK AUSTRALIA'S NEWSLETTER

Cell-based Research

Cultured Cells in Morning vs Evening Resistance Training Research

Sport science researchers have illustrated through in vitro C2C12 cellular differentiation in the presence of human sera sampled at varying exercise conditions, how diurnal hormonal variation may optimise musculoskeletal hypertrophy. Their article, titled "The Differential Hormonal Milieu of Morning versus Evening May Have an Impact on Muscle Hypertrophic Potential," was published in the journal PLOS One on 1 September 2016. The cell line, C2C12, used in the study was obtained from the European Collection of Authenticated Cell Cultures (ECACC; Porton Down, Salisbury, UK).

To read the article, click here.

Characterizing and Optimizing 3D Pancreatic Cancer Cell Cultures

Australian researchers have determined the efficacy of six current chemotherapeutics against a panel of primary and metastatic pancreatic tumor cell lines in a miniaturized extracellular matrix-based 3D cell culture system. Their article, titled "Assessing Drug Efficacy in a Miniaturized Pancreatic Cancer In Vitro 3D Cell Culture Model," was published in the journal ASSAY and Drug Development Technologies on 1 September 2016. A number of cell lines were used in the study including AsPC-1, BxPC-3, Mia-PaCa-2 and PANC-1.

To read the article, click here.

Investigating the Effects of Deferasirox Against Pancreatic Cancer

Researchers have evaluated the antiproliferative activity of deferasirox (DFX), a newly developed oral iron chelator, against pancreatic cancer in vitro and in vivo. Their article, titled "Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo," was published in the journal BMC Cancer on 31 August 2016. Three human pancreatic cancer cell lines, BxPC-3, HPAF-II and Panc 10.05, were used to examine the effects of DFX on cell cycle, proliferation and apoptosis.

To read the article, click here.

Recombinant Mumps Virus as a Cancer Therapeutic Agent

Researchers have described the construction and characterization of several recombinant mumps viruses and have presented initial data demonstrating their oncolytic activity against tumor cell lines in vitro. Their article, titled "Recombinant mumps virus as a cancer therapeutic agent," was published in the journal Molecular Therapy - Oncolytics on 10 August 2016. A number of cell lines were used in the study including Vero, ARH-77, Skov3, A549, HeLa, MPC11, AB12, EL-4 and C6. The AB12 cell line has been deposited exclusively in CellBank Australia by its originator.

To read the article, click here.

How CellBank Australia can Help

Catalog Deposit

CellBank Australia was established to make it cheaper and easier for researchers to access high quality cell lines and cell culture related services. We offer a free-of-charge Catalog Deposit service and have arrangements in place for the distribution and marketing of our unique cell lines outside of Oceania.

By making use of our service, depositors can simply refer cell line requests from interested parties to CellBank Australia or its distribution partners. This eliminates the need to culture, freeze and ship cell lines, saving on staff costs and workload. It also means that collaborators can save on shipping time and cost, which can be substantial, especially for overseas destinations. Consequently, a quicker pace of high quality research can be realized, for faster patient outcomes.

For more information about our Catalog Deposit service, click here.

CellBank Australia Cell Lines

We currently have 34 Australian derived cell lines that are unique to our collection:

*   Six mouse malignant mesothelioma cell lines

*   Four human malignant mesothelioma cell lines

*   Six human colorectal carcinoma cell lines

*   Three human Merkel carcinoma cell lines, and

*   Fifteen human malignant metastatic melanoma cell lines.

To learn more about our cell lines, click here.

Distribution of ECACC Cell Lines

CellBank Australia distributes more than 1,800 cell lines for ECACC to Australian and New Zealand researchers. For more information about ECACC's cell lines, click here.

Human Cell Authentication Testing

For human cells, CellBank Australia uses Short Tandem Repeat profiling to examine the number of tetranucleotide repeats at various loci to differentiate cell lines from different donors. CellBank Australia now offers human cell authentication testing for just ** $166 Australian dollars ** per sample, excluding GST.

For more information about our service, click here.

ComBio 2016

CellBank Australia is excited to participate as an exhibitor at Combio 2016.

ComBio 2016, which incorporates the annual meetings of a number of Australian and New Zealand Societies, is being held at the Brisbane Convention and Exhibition Centre (BCEC; Brisbane, QLD, AU) from 3 to 7 October 2016.

If you'll be at ComBio 2016, please stop by our booth to see me. I'm very keen to learn about your particular cell culture needs.